泰凌医药(01011.HK):"氨溴索"或具有治疗新型冠状病毒的潜力
格隆汇1月29日丨泰凌医药(01011.HK)公告,公司关注国内新闻平台《澎湃新闻》于日期为2020年1月28日的报导,有关报导指“氨溴索",以沐舒坦为人们所熟知,是一种呼吸道润滑祛痰药临床上常用于急慢性支气管炎等疾病。如今,中国科学家通过人工智能药靶筛选,发现其具有治疗新型冠状病毒(2019-nCoV)的潜力”。
同时,根据上述报导,“北京大学基础医学院副教授初明在接受《中国科学报》采访时表示,经过全面考虑,他们认为沐舒坦毒副作用较低,还是一种呼吸科常用药物,可考虑最先在临床治疗中观察”。
公司附属公司-苏州第壹制药有限公司拥有卓澳,一种"氨溴索"-(沐舒坦)的药物,公司将紧密注视新型冠状病毒(2019-nCoV)的治疗方法进程,一经确认"氨溴索"-(沐舒坦)能有效治疗新型冠状病毒,公司的生产部门将全力配合中国政府大量生产卓澳,一种"氨溴索"-(沐舒坦)的药物,以供应市场需要,与国家及人民一同全力抗疫。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.